To The Moon

The DJIA is partying like it’s 1999 with its 16th record high this year 🎉, while the Nasdaq quietly sat in a corner thinking about its life choices 😶‍🌫️📉. Meanwhile in healthcare land: • Eli Lilly (LLY) just casually crossed $1,000 like it’s buying kopi ☕😎 • Market cap almost $1 trillion — LLY said “Ozempic? Hold my syringe.” 💉🚀 • UNH jumped 5.8% in 2 days, basically waking up from a long nap like “I’m back, baby!” 😴➡️💥 Tech money is rotating into value stocks faster than Singaporeans chiong for bubble tea promos 🧋🏃‍♂️💨 So… 👉 Is Novo Nordisk now the “undervalued cousin who also got A for exam but nobody noticed”? 😅📉 👉 Will UNH keep running or is it panting already? 🏃‍♂️💦 Other value sectors climbing lately: Energy ⚡, Financials 🏦, Industrials 🛠️, and the eternal boomer favourite — Consumer

Love $Eli Lilly(LLY)$ The stock recent have a sting performance. What a great rally

I don’t think novo Nordisk is undervalued. Its antiobesity drug has been comparatively inferior compared to Eli Lilly’s and historically it also has been running into stock issues. So, I see it as inferior to Eli Lilly in both clinical performance and logistic capability which could be detrimental. Given novo Nordisk’s expected comparatively lower growth to Eli Lilly, Novo Nordisk is not undervalued and I prefer to buy a winner than a laggard. UNH has pulled back already. However, I believe the new leadership can turn things around. It is a major player for insurance in the US and trump looks set to introduce his own ways of keeping healthcare costs affordable for the Americans though not the same strategy as Obamacare. I expect premiums to pour in as Americans depend on it to keep their

nice

🌟🌟🌟Several  value stocks besides healthcare have been climbing recently.  They include : $Lockheed Martin(LMT)$ in the defense sector.  It is benefiting from increased US military spending and NATO contracts. $Exxon Mobil(XOM)$ is riding the energy boom.  Exxon has a great dividend yield of 3.5% and is well positioned for long term value as oil demand stabilises. $JPMorgan Chase(JPM)$ is benefiting from higher interest rates and strong loan growth.  It trades at a modest P/E ratio of 10 to 12 with consistent dividend increases.  JPMorgan is seen as a fortress bank with diversified revenue streams.

🌟🌟🌟 $UnitedHealth(UNH)$ surprised investors with stronger than expected Q3 25 results, signaling operational resilience. It is interesting to note that big institutions like Warren Buffett, David Tepper and Michael Burry have increased their stakes in UNH in 2025, citing undervaluation and durable cash flows. UNH trades at a Forward P/E ratio of 12 to 14.6, well below its historical average of 20.1. I believe that UNH has greater upside potential even though its share  price has rebounded recently.   It also has a dividend yield of 2.7%, which is a great source of passive income for income seeking investors while waiting for capital growth. @Tiger_comments

🌟🌟🌟Eli Lilly $Eli Lilly(LLY)$ and $Novo-Nordisk A/S(NVO)$ are the 2 health giants of the GLP-1 revolution.  But 2025 has rewritten their narratives. Riding the wave of Zepbound & Mounjaro, Lilly has become the darling of Wall Street.  Its stock price pierced through the USD 1000 mark, buoyed by Trump era drug pricing deals.  Investors see Lilly as politically aligned, commercially aggressive and structurally advantaged. Novo Nordisk's stock has plunged over 40%, punished by pricing fears and slower US uptake. Yet it remains profitable and more global intake. Ozempic, Wegovy have become global bestsellers.  Wegovy recently gained FDA approval for reducing cardiovascular risk, expan

Even this fella also 1T. It seems so easy to get so high

$UnitedHealth(UNH)$ $Eli Lilly(LLY)$ Whoa, the market's flipping the script faster than a plot twist in your favorite thriller! While the Nasdaq's nursing a hangover from overvalued tech dreams 😵‍💫, the Dow's flexing hard, clocking its 16th record close of 2025 and blasting past 48,000 like it's no big deal. That's the old-school economy roaring back, folks – think factories humming, banks lending, and energy flowing without the AI hype tax. This isn't just a blip; it's a full-blown sector rotation where value stocks are stealing the spotlight from growth darlings. Investors are piling into reliable earners with fat dividends and rock-solid balance sheets, betting on steady wins over moonshot gambles. If yo

Eli Lilly’s $Eli Lilly(LLY)$ rally highlights the ongoing shift from growth to value stocks. Its leadership in weight-loss drugs and upcoming oral GLP-1 launch make the $1 trillion valuation look increasingly justified. Demand is structural, not speculative, so I believe LLY still has room to run. Novo Nordisk $Novo-Nordisk A/S(NVO)$ , meanwhile, looks like a potential rebound play. With expectations reset after pricing pressure and cautious guidance, any stabilization in margins or faster oral semaglutide rollout could spark a recovery. I’d consider adding on dips. UnitedHealth’s $

Are we seriously referring to Reddit sentiments to reflect what the situation on the ground is... I get it, if you want to track a meme stock, by all means, look at Reddit because that would literally be a finger on the pulse. In the medium term, I think Novo Nordisk can still go up, but I wonder if GLP1 will start losing steam, what with China catching up to that trend and likely to produce viable alternatives that will be cheaper. I think UNH will similarly need the us government to prop them up to continue the ascend, otherwise it will likely lose steam. AI is always climbing, anything and everything wants to be called AI to bask in the glory and cash in on the lucrative investments.

On Wednesday, $Eli Lilly(LLY)$ jumped 2.95% to close at $1,017.78 per share, hitting another record high and bringing its market capitalization close to the $1 trillion mark. Founded 147 years ago, this pharmaceutical giant is now writing a new chapter in wealth creation at an astonishing pace.A quiet shift in market style is underwayThe Dow Jones Industrial Average, representing traditional economy stocks, has been setting new highs, while tech-heavy growth sectors are showing signs of fatigue. Analysts attribute this rotation to growing concerns over an AI bubble and renewed appreciation for value stocks. This transition from “pure growth” to “pure value” began in August and is now accelerating.The U.S. stock market is witnessing a clear style ro

$UnitedHealth(UNH)$ $Eli Lilly(LLY)$ Whoa, the market's flipping the script faster than a plot twist in your favorite thriller! While the Nasdaq's nursing a hangover from overvalued tech dreams 😵‍💫, the Dow's flexing hard, clocking its 16th record close of 2025 and blasting past 48,000 like it's no big deal. That's the old-school economy roaring back, folks – think factories humming, banks lending, and energy flowing without the AI hype tax. This isn't just a blip; it's a full-blown sector rotation where value stocks are stealing the spotlight from growth darlings. Investors are piling into reliable earners with fat dividends and rock-solid balance sheets, betting on steady wins over moonshot gambles. If yo

On Wednesday, $Eli Lilly(LLY)$ jumped 2.95% to close at $1,017.78 per share, hitting another record high and bringing its market capitalization close to the $1 trillion mark. Founded 147 years ago, this pharmaceutical giant is now writing a new chapter in wealth creation at an astonishing pace.A quiet shift in market style is underwayThe Dow Jones Industrial Average, representing traditional economy stocks, has been setting new highs, while tech-heavy growth sectors are showing signs of fatigue. Analysts attribute this rotation to growing concerns over an AI bubble and renewed appreciation for value stocks. This transition from “pure growth” to “pure value” began in August and is now accelerating.The U.S. stock market is witnessing a clear style ro

The DJIA is partying like it’s 1999 with its 16th record high this year 🎉, while the Nasdaq quietly sat in a corner thinking about its life choices 😶‍🌫️📉. Meanwhile in healthcare land: • Eli Lilly (LLY) just casually crossed $1,000 like it’s buying kopi ☕😎 • Market cap almost $1 trillion — LLY said “Ozempic? Hold my syringe.” 💉🚀 • UNH jumped 5.8% in 2 days, basically waking up from a long nap like “I’m back, baby!” 😴➡️💥 Tech money is rotating into value stocks faster than Singaporeans chiong for bubble tea promos 🧋🏃‍♂️💨 So… 👉 Is Novo Nordisk now the “undervalued cousin who also got A for exam but nobody noticed”? 😅📉 👉 Will UNH keep running or is it panting already? 🏃‍♂️💦 Other value sectors climbing lately: Energy ⚡, Financials 🏦, Industrials 🛠️, and the eternal boomer favourite — Consumer

I don’t think novo Nordisk is undervalued. Its antiobesity drug has been comparatively inferior compared to Eli Lilly’s and historically it also has been running into stock issues. So, I see it as inferior to Eli Lilly in both clinical performance and logistic capability which could be detrimental. Given novo Nordisk’s expected comparatively lower growth to Eli Lilly, Novo Nordisk is not undervalued and I prefer to buy a winner than a laggard. UNH has pulled back already. However, I believe the new leadership can turn things around. It is a major player for insurance in the US and trump looks set to introduce his own ways of keeping healthcare costs affordable for the Americans though not the same strategy as Obamacare. I expect premiums to pour in as Americans depend on it to keep their

Eli Lilly’s $Eli Lilly(LLY)$ rally highlights the ongoing shift from growth to value stocks. Its leadership in weight-loss drugs and upcoming oral GLP-1 launch make the $1 trillion valuation look increasingly justified. Demand is structural, not speculative, so I believe LLY still has room to run. Novo Nordisk $Novo-Nordisk A/S(NVO)$ , meanwhile, looks like a potential rebound play. With expectations reset after pricing pressure and cautious guidance, any stabilization in margins or faster oral semaglutide rollout could spark a recovery. I’d consider adding on dips. UnitedHealth’s $

🌟🌟🌟Eli Lilly $Eli Lilly(LLY)$ and $Novo-Nordisk A/S(NVO)$ are the 2 health giants of the GLP-1 revolution.  But 2025 has rewritten their narratives. Riding the wave of Zepbound & Mounjaro, Lilly has become the darling of Wall Street.  Its stock price pierced through the USD 1000 mark, buoyed by Trump era drug pricing deals.  Investors see Lilly as politically aligned, commercially aggressive and structurally advantaged. Novo Nordisk's stock has plunged over 40%, punished by pricing fears and slower US uptake. Yet it remains profitable and more global intake. Ozempic, Wegovy have become global bestsellers.  Wegovy recently gained FDA approval for reducing cardiovascular risk, expan

🌟🌟🌟Several  value stocks besides healthcare have been climbing recently.  They include : $Lockheed Martin(LMT)$ in the defense sector.  It is benefiting from increased US military spending and NATO contracts. $Exxon Mobil(XOM)$ is riding the energy boom.  Exxon has a great dividend yield of 3.5% and is well positioned for long term value as oil demand stabilises. $JPMorgan Chase(JPM)$ is benefiting from higher interest rates and strong loan growth.  It trades at a modest P/E ratio of 10 to 12 with consistent dividend increases.  JPMorgan is seen as a fortress bank with diversified revenue streams.

🌟🌟🌟 $UnitedHealth(UNH)$ surprised investors with stronger than expected Q3 25 results, signaling operational resilience. It is interesting to note that big institutions like Warren Buffett, David Tepper and Michael Burry have increased their stakes in UNH in 2025, citing undervaluation and durable cash flows. UNH trades at a Forward P/E ratio of 12 to 14.6, well below its historical average of 20.1. I believe that UNH has greater upside potential even though its share  price has rebounded recently.   It also has a dividend yield of 2.7%, which is a great source of passive income for income seeking investors while waiting for capital growth. @Tiger_comments

Are we seriously referring to Reddit sentiments to reflect what the situation on the ground is... I get it, if you want to track a meme stock, by all means, look at Reddit because that would literally be a finger on the pulse. In the medium term, I think Novo Nordisk can still go up, but I wonder if GLP1 will start losing steam, what with China catching up to that trend and likely to produce viable alternatives that will be cheaper. I think UNH will similarly need the us government to prop them up to continue the ascend, otherwise it will likely lose steam. AI is always climbing, anything and everything wants to be called AI to bask in the glory and cash in on the lucrative investments.

Love $Eli Lilly(LLY)$ The stock recent have a sting performance. What a great rally

nice

Even this fella also 1T. It seems so easy to get so high